Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.

NCT02728180 is registered in ClinicalTrials.gov with Dongzhimen Hospital, Beijing as lead sponsor.

NCT NCT02728180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.
Lead sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2016
Completion date
December 31, 2019
Enrollment
720 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke